Workflow
华润三九医药股份有限公司关于控股子公司昆药集团担保事项的进展公告
Shang Hai Zheng Quan Bao·2025-09-23 19:25

Core Viewpoint - The announcement details the progress of guarantees provided by China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. for its subsidiary Kunming Pharmaceutical Group, specifically for its wholly-owned subsidiaries [1][3][7] Summary by Sections Guarantee Overview - The total guarantee amount for the subsidiaries is set at 14 million RMB, with a cumulative guarantee balance of 39.8 million RMB already provided [1][2] - The guarantee is within the previously estimated limits and does not involve any counter-guarantees [2] Guarantee Progress - The guarantees are aimed at supporting the operational and business development needs of Kunming Pharmaceutical Group's subsidiaries [4] - The guarantee plan was approved during the board meeting and the annual shareholders' meeting [3] Company Information - The guaranteed companies, Xishuangbanna Dai Medicine and Dali Huirui Pharmaceutical, have a good credit status and are not listed as dishonest executors [5] Guarantee Agreement Details - The guarantee period lasts for three years from the date of the agreement [6] - Other shareholders of Dali Huirui have signed a maximum guarantee contract, with individual shareholders assuming joint guarantee responsibilities [6] Necessity and Reasonableness of Guarantee - The guarantees are deemed necessary to meet the production and operational needs of Kunming Pharmaceutical Group for 2025, enhancing financing efficiency and reducing costs [6] - The company maintains oversight of the financial status and cash flow of the guaranteed subsidiaries, ensuring manageable risk [6] Cumulative Guarantee Amounts - As of the announcement date, the total external guarantee balance for Kunming Pharmaceutical Group and its subsidiaries is 122.2 million RMB, representing 2.33% of the latest audited net assets [6] - The total guarantee limit for 2025 for Kunming Pharmaceutical Group and Tian Shi Li Pharmaceutical Group is 1.35615 billion RMB, accounting for 6.81% of the latest audited net assets [7]